Zosano Pharma Corp
NASDAQ:ZSAN
Income Statement
Earnings Waterfall
Zosano Pharma Corp
Revenue
|
660k
USD
|
Operating Expenses
|
-31.5m
USD
|
Operating Income
|
-30.9m
USD
|
Other Expenses
|
-24.3m
USD
|
Net Income
|
-55.2m
USD
|
Income Statement
Zosano Pharma Corp
Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||||||||||||
Revenue |
3
N/A
|
3
+14%
|
3
-6%
|
1
-48%
|
1
-28%
|
1
-35%
|
0
-54%
|
0
-69%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+118%
|
1
+40%
|
1
+37%
|
1
-14%
|
1
-16%
|
|
Gross Profit | |||||||||||||||||||||||||||||||||
Cost of Revenue |
(1)
|
(1)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
0
|
|
Gross Profit |
1
N/A
|
2
+26%
|
3
+52%
|
1
-46%
|
1
-28%
|
1
-35%
|
0
-54%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+200%
|
0
-7%
|
0
-64%
|
(0)
N/A
|
0
N/A
|
|
Operating Income | |||||||||||||||||||||||||||||||||
Operating Expenses |
(12)
|
(15)
|
(15)
|
(16)
|
(19)
|
(23)
|
(27)
|
(31)
|
(30)
|
(28)
|
(29)
|
(28)
|
(28)
|
(28)
|
(28)
|
(30)
|
(32)
|
(32)
|
(35)
|
(37)
|
(37)
|
(39)
|
(37)
|
(36)
|
(35)
|
(34)
|
(33)
|
(32)
|
(33)
|
(31)
|
(30)
|
(32)
|
|
Selling, General & Administrative |
(4)
|
(5)
|
(4)
|
(5)
|
(5)
|
(6)
|
(6)
|
(7)
|
(7)
|
(8)
|
(8)
|
(8)
|
(8)
|
(8)
|
(8)
|
(8)
|
(8)
|
(9)
|
(9)
|
(10)
|
(10)
|
(11)
|
(12)
|
(12)
|
(12)
|
(12)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
(11)
|
|
Research & Development |
(7)
|
(10)
|
(11)
|
(11)
|
(13)
|
(17)
|
(20)
|
(23)
|
(22)
|
(21)
|
(20)
|
(19)
|
(20)
|
(20)
|
(20)
|
(21)
|
(24)
|
(24)
|
(26)
|
(26)
|
(26)
|
(27)
|
(25)
|
(24)
|
(23)
|
(22)
|
(22)
|
(21)
|
(22)
|
(22)
|
(21)
|
(20)
|
|
Operating Income |
(10)
N/A
|
(13)
-31%
|
(13)
+5%
|
(14)
-13%
|
(18)
-23%
|
(23)
-30%
|
(26)
-16%
|
(30)
-16%
|
(30)
+3%
|
(28)
+4%
|
(29)
-1%
|
(28)
+4%
|
(28)
-1%
|
(28)
-2%
|
(28)
+0%
|
(30)
-5%
|
(32)
-8%
|
(32)
-2%
|
(35)
-7%
|
(37)
-6%
|
(37)
-2%
|
(39)
-4%
|
(37)
+4%
|
(36)
+2%
|
(35)
+5%
|
(34)
+3%
|
(33)
+2%
|
(32)
+2%
|
(32)
-1%
|
(31)
+5%
|
(30)
+3%
|
(31)
-3%
|
|
Pre-Tax Income | |||||||||||||||||||||||||||||||||
Interest Income Expense |
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Non-Reccuring Items |
4
|
4
|
1
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
(24)
|
|
Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(8)
N/A
|
(11)
-48%
|
(14)
-26%
|
(16)
-16%
|
(20)
-22%
|
(25)
-25%
|
(28)
-13%
|
(32)
-12%
|
(31)
+3%
|
(30)
+4%
|
(30)
0%
|
(29)
+4%
|
(29)
-1%
|
(29)
-1%
|
(29)
+1%
|
(30)
-4%
|
(32)
-7%
|
(33)
-1%
|
(35)
-8%
|
(37)
-3%
|
(37)
-1%
|
(39)
-5%
|
(38)
+3%
|
(37)
+2%
|
(35)
+4%
|
(34)
+3%
|
(33)
+2%
|
(33)
+2%
|
(31)
+5%
|
(31)
+0%
|
(30)
+4%
|
(55)
-84%
|
|
Net Income | |||||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(8)
|
(11)
|
(14)
|
(16)
|
(20)
|
(25)
|
(28)
|
(32)
|
(31)
|
(30)
|
(30)
|
(29)
|
(29)
|
(29)
|
(29)
|
(30)
|
(32)
|
(33)
|
(35)
|
(37)
|
(37)
|
(39)
|
(38)
|
(37)
|
(35)
|
(34)
|
(33)
|
(33)
|
(31)
|
(31)
|
(30)
|
(55)
|
|
Net Income (Common) |
(8)
N/A
|
(11)
-48%
|
(14)
-26%
|
(16)
-16%
|
(20)
-22%
|
(25)
-25%
|
(28)
-13%
|
(32)
-12%
|
(31)
+3%
|
(30)
+4%
|
(30)
0%
|
(29)
+4%
|
(29)
-1%
|
(29)
-1%
|
(29)
+1%
|
(30)
-4%
|
(32)
-7%
|
(33)
-1%
|
(35)
-8%
|
(37)
-3%
|
(37)
-1%
|
(39)
-5%
|
(38)
+3%
|
(37)
+2%
|
(35)
+4%
|
(34)
+3%
|
(33)
+2%
|
(33)
+2%
|
(31)
+5%
|
(31)
+0%
|
(30)
+4%
|
(55)
-84%
|
|
EPS (Diluted) |
-29.31
N/A
|
-41.51
-42%
|
-54.77
-32%
|
-33.57
+39%
|
-33.53
+0%
|
-41.77
-25%
|
-47.38
-13%
|
-53.28
-12%
|
-51.52
+3%
|
-41.89
+19%
|
-35.52
+15%
|
-28.16
+21%
|
-14.77
+48%
|
-14.98
-1%
|
-14.78
+1%
|
-15.39
-4%
|
-2.76
+82%
|
-2.73
+1%
|
-2.95
-8%
|
-3.06
-4%
|
-2.2
+28%
|
-2.18
+1%
|
-2
+8%
|
-1.02
+49%
|
-0.64
+37%
|
-0.44
+31%
|
-0.33
+25%
|
-0.31
+6%
|
-9.99
-3 123%
|
-9.38
+6%
|
-8.8
+6%
|
-12.99
-48%
|